Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (4): 1-7.doi: 10.6040/j.issn.1671-7554.0.2017.1293
CHEN Shiling, ZHOU Xingyu
CLC Number:
| [1] Committee on Gynecologic Practice. Committee opinion No. 698: hormone therapy in primary ovarian insufficiency[J]. Obstet Gynecol, 2017, 129(5): e134-e141. [2] Committee opinion No. 605: primary ovarian insufficiency in adolescents and young women[J]. Obstet Gynecol, 2014, 124(1): 193-197. [3] The ESHRE Guideline Group on POI, Webber L, Davies M, et al. ESHRE Guideline: management of women with premature ovarian insufficiency[J]. Hum Reprod, 2016, 31(5): 926-937. [4] 陈子江, 田秦杰, 乔杰, 等. 早发性卵巢功能不全的临床诊疗中国专家共识[J]. 中华妇产科杂志, 2017, 52(9): 577-581. [5] Tal R, Seifer DB. Ovarian reserve testing: a users guide[J]. Am J Obstet Gynecol, 2017, 217(2): 129-140. [6] Visser JA, Schipper I, Laven JS, et al. Anti-mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency[J]. Nat Rev Endocrinol, 2012, 8(6): 331-341. [7] Knauff EAH, Eijkemans MJC, Lambalk CB, et al. Anti-müllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure[J]. J Clin Endocrinol Metab, 2009, 94(3): 786-792. [8] Kallio S, Aittomaki K, Piltonen T, et al. Anti-mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries[J]. Hum Reprod, 2012, 27(3): 854-860. [9] Jiao X, Zhang H, Ke H, et al. Premature ovarian insufficiency: phenotypic characterization within different etiologies[J]. J Clin Endocrinol Metab, 2017, 102(7): 2281-2290. [10] Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure[J]. Clin Endocrinol, 2008, 68(4): 499-509. [11] Shestakova IG, Radzinsky VE, Khamoshina MB. Occult form of premature ovarian insufficiency[J]. Gynecol Endocrinol, 2016, 32(sup2): 30-32. [12] Streuli I, Fraisse T, Ibecheole V, et al. Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency[J]. Fertil Steril, 2009, 92(2): 464-470. [13] Kushnir VA, Safdie M1, Darmon SK, et al. Age-specific IVF outcomes in infertile women with baseline FSH levels ≥20 mIU/mL[J]. Reprod Sci, 2017: 1933719117697130. doi:10.1177/1933719117697130. [14] Tucker EJ, Grover SR, Bachelot A, et al. Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic spectrum[J]. Endocr Rev, 2016, 37(6): 609-635. [15] Lakhal B, Braham R, Berguigua R, et al. Cytogenetic analyses of premature ovarian failure using karyotyping and interphase fluorescence in situ hybridization(FISH)in a group of 1000 patients[J]. Clin Genet, 2010, 78(2): 181-185. [16] Baronchelli S, Conconi D, Panzeri E, et al. Cytogenetics of premature ovarian failure: an investigation on 269 affected women[J]. J Biomed Biotechnol, 2011, 2011: 370195. doi:10.1155/2011/370195. [17] Jiao X, Qin C, Li J, et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure[J]. Hum Reprod, 2012, 27(7): 2201-2207. [18] Kalantari H, Madani T, Zari MS, et al. Cytogenetic analysis of 179 Iranian women with premature ovarian failure[J]. Gynecol Endocrinol, 2013, 29(6): 588-591. [19] Rossetti R, Ferrari I, Bonomi M, et al. Genetics of primary ovarian insufficiency[J]. Clin Genet, 2017, 91(2): 183-198. [20] Guo T, Qin Y, Jiao X, et al. FMR1 Premutation is an uncommon explanation for premature ovarian failure in han Chinese[J]. PLoS One, 2014, 9(7): e103316. doi:10.1371/journal.pone.0103316. [21] Qin Y, Jiao X, Simpson JL, et al. Genetics of primary ovarian insufficiency: new developments and opportunities[J]. Hum Reprod Update, 2015, 21(6): 787-808. [22] Tšuiko O, Nõukas M, Žilina O, et al. Copy number variation analysis detectsnovel candidate genes involved infollicular growth and oocyte maturationin a cohort of premature ovarian failure cases[J]. Hum Reprod, 2016, 31(8): 1913-1925. [23] Komorowska B. Autoimmune premature ovarian failure[J]. Prz Menopauzalny, 2016, 15(4): 210-214. [24] Gao J, Jiao X, Dang Y, et al. Identification of patients with primary ovarian insufficiency caused by autoimmunity[J]. Reprod Biomed Online, 2017, 35(4): 475-479. [25] Forges T, Monnier-Barbarino P, Faure GC, et al. Autoimmunity and antigenic targets in ovarian pathology[J]. Hum Reprod Update, 2004, 10(2): 163-175. [26] Dragojevic-Dikic S, Marisavljevic D, Mitrovic A, et al. An immunological insight into premature ovarian failure(POF)[J]. Autoimmun Rev, 2010, 9(11): 771-774. [27] Silva CA, Yamakami LYS, Aikawa NE, et al. Autoimmune primary ovarian insufficiency[J]. Autoimmun Rev, 2014, 13(4-5): 427-430. [28] Mohamed AA, Al-Hussaini TK, Fathalla MM, et al. The impact of excision of benign nonendometriotic ovarian cysts on ovarian reserve: a systematic review[J]. Am J Obstet Gynecol, 2016, 215(2): 169-176. [29] Ye X, Yang Y, Sun X. A retrospective analysis of the effect of salpingectomyon serum anti-Müllerian hormonelevel and ovarian reserve[J]. Am J Obstet Gynecol, 2015, 212(1): 51-53. [30] Irtan S, Orbach D, Helfre S, et al. Ovarian transposition in prepubescent and adolescent girls with cancer[J]. Lancet Oncol, 2013, 14(13): e601-e608. [31] Overbeek A, van den Berg MH, van Leeuwen FE, et al. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review[J]. Cancer Treat Rev, 2017, 53: 10-24. [32] Keilholz U, Korbling M, Fehrentz D, et al. Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders[J]. Cancer, 1989, 64(3): 641-645. [33] Whitehead E, Shalet SM, Blackledge G, et al. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease[J]. Cancer, 1983, 52(6): 988-993. [34] 俞健梅, 马艳萍, 李永刚, 等. 环境内分泌干扰物对生殖健康影响的研究进展[J]. 现代生物医学进展, 2014, 14(31): 6197-6200. YU Jianmei, MA Yanping, LI Yonggang, et al. The research progress on the effect of the reproductive health by the environmental endocrine disruptors[J]. Progress in Modern Biomedicine, 2014, 14(31): 6197-6200. [35] Vabre P, Gatimel N, Moreau J, et al. Environmental pollutants, a possible etiology for premature ovarian insufficiency: a narrative review of animal and human data[J]. Environ Health, 2017, 16(1): 37. doi:10.1186/s12940-017-0242-4. [36] Nelson LM. Primary ovarian insufficiency[J]. N Engl J Med, 2009, 360(6): 606-614. [37] Bachelot A, Nicolas C, Bidet M, et al. Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency[J]. Clin Endocrinol, 2017, 86(2): 223-228. [38] Chen X, Chen SL, Ye DS, et al. Retrospective analysis of reproductive outcomes in women with primary ovarian insufficiency showing intermittent follicular development[J]. Reprod Biomed Online, 2016, 32(4): 427-433. [39] 马伟旭, 陈薪, 周星宇, 等. 早发性卵巢功能不全患者应用卵胞浆内单精子显微注射-胚胎移植获妊娠分娩1例及文献复习[J]. 南方医科大学学报, 2017, 37(10): 1418-1422. MA Weixu, CHEN Xin, ZHOU Xingyu, et al. Successful pregnancy following intracytoplasmic sperm injection-embryo transfer in a patient with premature ovarian insufficiency: a case report[J]. J South Med Univ, 2017, 37(10): 1418-1422. [40] Ben-Nagi J, Panay N. Premature ovarian insufficiency: how to improve reproductive outcome?[J]. Climacteric, 2014, 17(3): 242-246. [41] Kawamura K, Yuan C, Suzuki N, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment[J]. Proc Natl Acad Sci USA, 2013, 110(43): 17474-17479. [42] Oyesanya OA, Olufowobi O, Ross W, et al. Prognosis of oocyte donation cycles: a prospective comparison of the in vitro fertilization-embryo transfer cycles of recipients who used shared oocytes versus those who used altruistic donors[J]. Fertil Steril, 2009, 92(3): 930-936. [43] Podfigurna-Stopa A, Czyzyk A, Grymowicz M, et al. Premature ovarian insufficiency: the context of long-term effects[J]. J Endocrinol Invest, 2016, 39(9): 983-990. [44] 廖彩韵, 梁晓燕. 女性生育力保存研究进展[J]. 实用妇产科杂志, 2013, 29(5): 339-342. [45] Lara LA, Useche B, Ferriani RA, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response[J]. J Sex Med, 2009, 6(1): 30-39. [46] Benetti-Pinto CL, Giraldo PC, Pacello PCC, et al. Vaginal epithelium and microflora characteristics in women with premature ovarian failure under hormone therapy compared to healthy women[J]. Arch Gynecol Obstet, 2015, 292(1): 159-164. [47] Daan N, Muka T, Koster M, et al. Cardiovascular risk in women with premature ovarian insufficiency compared to premenopausal women at middle age[J]. J Clin Endocrinol Metab, 2016, 101(9): 3306-3315. [48] Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis[J]. JAMA Cardiol, 2016, 1(7): 767-776. [49] Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause[J]. Fertil Steril, 2016, 106(7): 1588-1599. [50] Wu X, Cai H, Kallianpur A, et al. Impact of premature ovarian failure on mortality and morbidity among Chinese women[J]. PLoS One, 2014, 9(3): e89597. doi:10.1371/journal.pone.0089597. [51] Asli IN, Fallahian M, Seddigh HR, et al. Evaluation of bone mineral density in premature ovarian failure[J]. Hell J Nucl Med, 2010, 13(3): 261-263. [52] Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women[J]. J Clin Endocrinol Metab, 2009, 94(7): 2277-2283. [53] Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement[J]. J Clin Endocrinol Metab, 2014, 99(9): 3418-3426. [54] Schmidt PJ, Cardoso GM, Ross JL, et al. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure[J]. JAMA, 2006, 295(12): 1374-1376. |
| [1] | HAO Guimin, LUO Zhuoye, WANG Yizhuo. Ethical issues and considerations in fertility preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 47-52. |
| [2] | LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46. |
| [3] | LU Qun, ZHAO Lulu. Progress on assisted reproductive technology for women with atypical endometrial hyperplasia and endometrial carcinoma receiving fertilitysparing treatment [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 35-41. |
| [4] | YAN Lei, YUE Caixin, LIU Yichun. Fertility preservation in patients with endometriosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 31-34. |
| [5] | SHI Yuhua, PAN Ye, XIE Yanqiu. Latest advances of embryo cryopreservation technology [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 12-18. |
| [6] | WU Ruifang, LI Changzhong. Status and progress of female fertility protection [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 1-7. |
| [7] | RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30. |
| [8] | Xiaohui DENG,Ling GUO. Applications and progress of immunotherapy in repeated implantation failure [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 32-37. |
| [9] | ZHU Xuli, ZHOU Liang, WANG Yue, SUN Qingyun, CAO Mingya, DU Yuanjie, CAO Jinfeng, ZHAO Zhiming, HAO Guimin. Correlation analysis of freezing methods with different sperm sources and pregnancy outcomes [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 86-93. |
|
||
